Informações:
Falhas:
ID
43585
Descrição
Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2; ODM derived from: https://clinicaltrials.gov/show/NCT00363012
Link
https://clinicaltrials.gov/show/NCT00363012
Palavras-chave
Versões (2)
- 13/01/2017 13/01/2017 -
- 20/09/2021 20/09/2021 -
Transferido a
20 de setembro de 2021
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Cancer NCT00363012
Eligibility Breast Cancer NCT00363012
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00363012
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Breast Carcinoma TNM clinical staging
Item
diagnosis of stage iii/iv breast cancer
boolean
C0678222 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,2])
Chemotherapy Completed
Item
completed chemotherapy
boolean
C0392920 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,2])
trastuzumab | Herceptin
Item
receiving trastuzumab (herceptin®) monotherapy
boolean
C0728747 (UMLS CUI [1])
C0338204 (UMLS CUI [2])
C0338204 (UMLS CUI [2])
HER-2/neu intracellular domain protein Plasmid vaccine | Clinical Trial Completed Successful
Item
successful completion of her-2/neu (her2) intracellular domain (icd) plasmid-based vaccine trial (protocol 01-9773-d06: "a phase i safety and efficacy trial of a dna plasmid based vaccine encoding the her-2/neu intracellular domain in subjects with her-2/neu-overexpressing tumors") within the past 3 months
boolean
C3146228 (UMLS CUI [1,1])
C0597641 (UMLS CUI [1,2])
C0008976 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C1272703 (UMLS CUI [2,3])
C0597641 (UMLS CUI [1,2])
C0008976 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C1272703 (UMLS CUI [2,3])
Hormone Receptor Status Unspecified
Item
hormone receptor status not specified
boolean
C0019929 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
C0205370 (UMLS CUI [1,3])
C0449438 (UMLS CUI [1,2])
C0205370 (UMLS CUI [1,3])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Gender
Item
male or female (male patients are not excluded)
boolean
C0079399 (UMLS CUI [1])
Menopausal Status Unspecified
Item
menopausal status not specified
boolean
C3829127 (UMLS CUI [1,1])
C0205370 (UMLS CUI [1,2])
C0205370 (UMLS CUI [1,2])
Zubrod Performance Status
Item
zubrod performance status 0
boolean
C3714786 (UMLS CUI [1])
Gender Childbearing Potential Lacking
Item
unable to bear children (female patients)
boolean
C0079399 (UMLS CUI [1,1])
C3831118 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,3])
C3831118 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
disease characteristic
Item
see disease characteristics
boolean
C0599878 (UMLS CUI [1])
Chemotherapy Cytoreductive
Item
no cytoreductive chemotherapy within the past 30 days
boolean
C0392920 (UMLS CUI [1,1])
C0864494 (UMLS CUI [1,2])
C0864494 (UMLS CUI [1,2])
Cytotoxic therapy | CORTICOSTEROIDS FOR SYSTEMIC USE
Item
no cytotoxic treatment and/or systemic corticosteroids within the past month
boolean
C0677881 (UMLS CUI [1])
C3653708 (UMLS CUI [2])
C3653708 (UMLS CUI [2])
Therapeutic radiology procedure Local | Hormone Therapy
Item
concurrent local radiotherapy or hormonal therapy allowed
boolean
C1522449 (UMLS CUI [1,1])
C0205276 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2])
C0205276 (UMLS CUI [1,2])
C0279025 (UMLS CUI [2])